Insiders At Krystal Biotech Sold US$16m In Stock, Alluding To Potential Weakness
Insiders At Krystal Biotech Sold US$16m In Stock, Alluding To Potential Weakness
Over the past year, many Krystal Biotech, Inc. (NASDAQ:KRYS) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying versus if they selling is usually more beneficial, as the latter can be open to many interpretations. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在过去的一年中,很多 克里斯塔尔生物技术有限公司 纳斯达克股票代码:KRYS)内部人士出售了该公司的大量股份,这可能激起了投资者的兴趣。在评估内幕交易时,了解内部人士是买入还是卖出通常更有利,因为后者可能有多种解释。但是,如果有几位内部人士在特定时间段内出售股票,股东应更深入地研究。
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
尽管我们认为股东不应简单地关注内幕交易,但我们确实认为密切关注内部人士的所作所为是完全合乎逻辑的。
Check out our latest analysis for Krystal Biotech
看看我们对克里斯塔尔生物技术的最新分析
The Last 12 Months Of Insider Transactions At Krystal Biotech
Krystal Biotech过去12个月的内幕交易
The Lead Independent Director, Daniel Janney, made the biggest insider sale in the last 12 months. That single transaction was for US$6.4m worth of shares at a price of US$129 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$116). So it is hard to draw any strong conclusion from it.
首席独立董事丹尼尔·詹尼进行了过去12个月来最大规模的内幕出售。该单笔交易涉及价值640万美元的股票,每股价格为129美元。虽然我们通常不喜欢看到内幕销售,但更令人担忧的是销售是否以较低的价格进行。一线希望是,此次抛售高于最新价格(116美元)。因此,很难从中得出任何有力的结论。
In the last year Krystal Biotech insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
去年,Krystal Biotech的内部人士没有购买任何公司股票。下图显示了去年的内幕交易(按公司和个人划分)。点击下图,你可以看到每笔内幕交易的确切细节!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231003/0-aa9d5fdd7fbe11ad9ec10ae45c42ddd4-0-acaa3e10d51878736bb08239652a3238.png/big)
I will like Krystal Biotech better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些大规模的内幕买入,我会更喜欢Krystal Biotech的。在我们等待的时候,看看这个 免费的 最近有大量内幕收购的成长型公司名单。
Insider Ownership Of Krystal Biotech
克里斯塔尔生物科技的内部所有权
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Krystal Biotech insiders own 13% of the company, currently worth about US$412m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
对于普通股股东来说,值得查看公司内部人士持有多少股票。通常,内部人所有权越高,内部人士被激励长期建立公司的可能性就越大。Krystal Biotech内部人士拥有该公司13%的股份,按最近的股价计算,目前价值约为4.12亿美元。内部人士的这种重要所有权通常会增加公司为所有股东的利益而经营的机会。
So What Does This Data Suggest About Krystal Biotech Insiders?
那么这些数据对Krystal Biotech内部人士有什么启示呢?
The fact that there have been no Krystal Biotech insider transactions recently certainly doesn't bother us. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Krystal Biotech insider transactions don't fill us with confidence. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For instance, we've identified 2 warning signs for Krystal Biotech (1 is significant) you should be aware of.
最近没有Krystal Biotech的内幕交易,这一事实当然不会打扰我们。令人振奋的是,内部人士拥有大量股票,但我们希望看到更多的内幕买盘,因为去年的Krystal Biotech内幕交易并没有使我们充满信心。因此,这些内幕交易可以帮助我们建立关于股票的论点,但了解这家公司面临的风险也是值得的。例如,我们已经确定 Krystal Biotech的两个警告信号 (1 很重要)你应该注意。
Of course Krystal Biotech may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然 克里斯塔尔生物技术可能不是最值得买入的股票。所以你可能希望看到这个 免费的 高品质公司的集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。